TrialBlood advances2020

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.

Meletios Dimopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.